A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HR+/HER2- Advanced and/or Metastatic Breast Cancer
Interventions: DRUG: HS-10342
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.